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ABSTRACT
Microcephaly with early-onset, intractable seizures
and developmental delay (MCSZ) is a hereditary
disease caused by mutations in polynucleotide
kinase/phosphatase (PNKP), a DNA strand break
repair protein with DNA 50-kinase and DNA 30-phos-
phatase activity. To investigate the molecular basis
of this disease, we examined the impact of MCSZ
mutations on PNKP activity in vitro and in cells.
Three of the four mutations currently associated with
MCSZ greatly reduce or ablate DNA kinase activity of
recombinant PNKP at 30 C (L176F, T424Gfs48X and
exon15"fs4X), but only one of these mutations
reduces DNA phosphatase activity under the same
conditions (L176F). The fourth mutation (E326K) has
littleimpactoneitherDNAkinaseorDNAphosphatase
activity at 30 C, but is less stable than the wild-type
enzyme at physiological temperature. Critically, all of
the MCSZ mutations identified to date result in
 10-fold reduced cellular levels of PNKP protein,
and reduced rates of chromosomal DNA strand
break repair. Together, these data suggest that all
four known MCSZ mutations reduce the cellular
stability and level of PNKP protein, with three muta-
tions likely ablating cellular DNA 50-kinase activity
and all of the mutations greatly reducing cellular
DNA 30-phosphatase activity.
INTRODUCTION
Discontinuities in one strand of the DNA double helix,
denoted DNA single-strand breaks (SSBs), are the most
commonly occurring type of DNA lesion in cells, with tens
of thousands arising per cell per day (1,2). SSBs can arise
either directly from the disintegration of damaged sugars
or indirectly from abortive topoisomerase 1 activity
or during the removal of damaged DNA bases or
deoxyribose by DNA base excision repair. If not
repaired quickly enough, SSBs can block transcription
or result in the formation of DNA double-strand breaks
(DSBs) during DNA replication (3,4). One source of SSBs
is attack of DNA by reactive oxygen species (ROS)
generated during normal cellular metabolism (5–7). To
counter this threat, cells employ a number of DNA
repair pathways collectively termed DNA single-strand
break repair (SSBR) to ensure the rapid and efﬁcient
removal of SSBs (8).
SSBR typically involves four stages of repair: detection
of the break, DNA end processing, DNA gap ﬁlling and
DNA ligation. During DNA end processing, ‘damaged’
DNA termini are restored to conventional 30-hydroxyl
and 50-phosphate moieties to enable subsequent steps of
SSBR to occur. Enzymatically, this is the most diverse step
because of the variety of types of damaged DNA termini
that can arise. The importance of DNA end processing is
indicated by the existence of neuropathological disorders
in which proteins involved this process are mutated. These
are ataxia oculomotor apraxia-1 (AOA1), spinocerebellar
ataxia with axonal neuropathy-1 (SCAN1) and micro-
cephaly with early-onset intractable seizures and develop-
mental delay (MCSZ), which are caused by mutations in
aprataxin (APTX), tyrosyl–DNA phosphodiesterase 1
(TDP1) and polynucleotide kinase/phosphatase (PNKP),
respectively (9–12). A striking feature of these diseases is
that they lack any major extraneurological symptoms,
suggesting that the development and/or maintenance of
neurones is hypersensitive to defects in DNA end
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disorders, however. For example, whereas MCSZ is pri-
marily a developmental disease, associated with primary
microcephaly and seizures from an early age, AOA1 and
SCAN1 are progressive, degenerative, disorders.
MCSZ is the most recent disease identiﬁed in which the
rate of SSBR is reduced. PNKP, the protein mutated in
MCSZ, is a bi-functional enzyme that possesses both
DNA 30-phosphatase and DNA 50-kinase activities.
PNKP is a modular protein that possesses three distinct
domains; an amino-terminal fork-head-associated domain
(FHA) that mediates interactions with the SSBR and
double-strand break repair (DSBR) scaffold proteins
XRCC1 andXRCC4,respectively andtheDNAphosphat-
ase and DNA kinase catalytic domains (13–15). PNKP is a
component of both SSBR and DSBR pathways and most
likely operates at the majority of DNA breaks arising from
attack of deoxyribose by ROS, because 50–70% of such
breaks harbour 30-phosphate termini (2,6). In addition,
DNA strand breaks resulting from abortive topoisomer-
ase 1 (Top1) activity or created by bi-functional DNA
glycosylases during DNA base excision repair can also
harbour 30-phosphate termini (6,16,17).
To date, four mutations in PNKP have been identiﬁed in
MCSZ (12). L176F and E326K are point mutations of
highly conserved residues within the DNA phosphatase
domain and T424Gfs48X and exon15fs4X are
frame-shift mutations in the DNA kinase domain that
result in premature stop codons and truncated PNKP
polypeptides (Figure 1). T424Gfs48X is the result of a
17-bp duplication within exon14 in the kinase domain,
resulting in a 471 amino acid polypeptide of which the
last 48 residues are out-of-frame. Exon15fs4X results in
a 17-bp deletion within intron 15 that leads to mRNA
transcript lacking exon 15, resulting in a polypeptide of
436 amino acids of which the last four residues are
out-of-frame (12). E326K and T424Gfs48X are the
commonest MCSZ mutations reported to date, with
seven individuals homozygous for E326K and three homo-
zygous for T424Gfs48X. Additionally, four MCSZ individ-
uals possessing the T424Gfs48X mutation are compound
heterozygotes, harbouring the additional mutations L176F
or exon15fs4X. Here we have analysed the impact of the
MCSZ mutations on the speciﬁc activities of PNKP, to
establish the molecular basis of this disease.
MATERIALS AND METHODS
DNA constructs
pET16b–PNKP encoding His-tagged human PNKP has
been described previously (13). pET16b–PNKP
D171N
encodes a His-tagged phosphatase deﬁcient PNKP mutant
thatwassub-clonedfrompCD2E-PNK
D171N (18). pET16b–
PNKP
L176F, pET16b–PNKP
E326K, pET16b–
PNKP
T424Gfs48X and pET16b–PNKP
exon15fs4X encode
His-tagged PNKP proteins harbouring MCSZ mutations.
pET16b–PNKP
L176F and pET16b–PNKP
E326K were
created by site-directed mutagenesis of pET16b–PNKP
using a QuikChange XL mutagenesis kit (Agilent
Technologies) and the primer sets [50-ATCTGGACGGGA
CGTTCATCACCACACGC-30/50-GCGTGTGGTGAT
GAACGTCCCGTCCAGAT-30; pET16b–PNKP
L176F]
and [50-CTTCGCCACGCCTGAGAAGTTCTTTCTCA
AGTG-30/50-CACTTGAGAAAGAACTTCTCAGGCG
TGGCGAAG-30; pET16b–PNKP
L176F], respectively.
pET16b–PNKP
T424Gfs48X and pET16b–PNKP
exon15fs4X
were generated by RT–PCR ampliﬁcation of the PNKP
region spanning the 17-bp duplication in T424Gfs48X
(using the primers 50-AAA GAC TTC TCC TGC GCC
GAT CG-30 and 50-CTC CAC CCA TAG CCG GAA
CG-30) and the region deleted from exon15 in
exon15fs4X (using the primers 50- AAA GAC TTC
TCC TGC GCC GAT CG-30 and 50-TTT GGA TCC
TTC AGC CCT CGG AGA ACT GGC A-30), using
mRNA extracted from the compound heterozygote
MCSZ lymphoblastoid cell line, MC22602. The PCR frag-
ments harbouring the truncation mutations were then
sub-cloned into pET16b–PNKP using SacI/AgeI
(pET16b–PNKP
T424Gfs48X) and SacI/BamHI (pET16b–
PNKP
exon15fs4X). pEYFP-PNKP, pEYFP-PNKP
L176F,
pEYFP-PNKP
E326K, pEYFP-PNKP
T424Gfs48X and
pEYFP-PNKP
exon15fs4X are mammalian expression
vectors encoding YFP-tagged wild-type (WT) and mutant
PNKP and were created by PCR ampliﬁcation of the
PNKP ORF in pET16b–PNKP, pET16b–PNKP
L176F,
pET16b–PNKP
E326K, pET16b–PNKP
T424Gfs48X and
pET16b–PNKP
exon15fs4X, respectively, using the primers
50-AAA GAT CTA AAA TGG GCG AGG TGG AGG
CC-30 and 50-AAA AGC TTA AAT CAG CCC TCG
GAG AAC TGG C-30 and sub-cloning the ampliﬁed
products into pEYFP-C1 (Clontech) using BglII/HindIII.
Figure 1. PNKP mutations in MCSZ. (A) Schematic depicting the four
PNKP mutations identiﬁed in MCSZ, to date. Note that two point
mutations (L176F and E326K) are located in the DNA phosphatase
domain and two frame-shift mutations (T424Gfs48X and
exon15fs4X), resulting in premature stop codons and truncated
PNKP protein, are located in the DNA kinase domain. FHA denotes
the fork-head-associated domain. (B) PNKP genotype of known MCSZ
families, unaffected relatives, and associated LCLs used in this study.
All individuals and families have been described previously (12).
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His-tagged recombinant PNKP was expressed in the
Escherichia coli strain BL21 (DE3) for 90min at 20 C
following the addition of 1mM IPTG. Cells were
sonicated in 50mM Tris–HCl (pH 7.5), 0.5M NaCl,
10% glycerol, 1mM DTT, 1mM imidazole (pH 8.0),
1mM PMSF and clariﬁed by centrifugation. His-PNKP
was puriﬁed by immobilized metal chelate chromatog-
raphy (IMAC) using Ni–NTA Agarose resin (Qiagen),
washing successively with wash buffer [50mM Tris–HCl
(pH 7.5), 0.5M NaCl, 10% glycerol, 1mM DTT] contain-
ing either 20mM (10 CV), 40mM (10 CV) or 80mM
(10 CV) imidazole, and eluting in wash buffer containing
250mM imidazole. Elution fractions containing
His-PNKP were pooled, EDTA added to 10mM to
chelate eluted nickel ions (19), and dialysed in 50mM
Tris–HCl pH 7.5, 0.1M NaCl, 10% glycerol, 1mM
DTT. With the exception of His-PNKP
L176F, His-PNKP
was then further puriﬁed by cation exchange chromatog-
raphy and a 0.1–1M NaClgradient on a Mono S 5/50 GL
column and A ¨ KTA Puriﬁer UPC 10 system (GE
Healthcare). Finally, elution fractions containing recom-
binant PNKP were dialysed [25mM Tris–HCl, 150mM
NaCl, 10% glycerol, 1mM DTT], aliquoted and snap
frozen in liquid nitrogen and stored at  80 C.
Preparation of oligonucleotide duplex substrates
Oligonucleotide duplexes containing a SSB with a 1-bp gap
andeither30-and5 0-phosphateterminior30-and5 0-hydroxyl
terminiwerepreparedbyannealinga17-meroligonucleotide
(50-TCCGTTGAAGCCTGCTT-30)h a r b o u r i n ga3 0-phos-
phate or 30-hydroxyl terminus (as appropriate) and a
25-mer oligonucleotide (50-GACATACTAACTTGAGCG
AAACGGT-30) harbouring a 50-phosphate or 50-hydroxyl
terminus (as appropriate) with a 43-mer (50-CCGTTTCGC
TCAAGTTAGTATGTCAAAGCAGGCTTCAACGG
AT-30). Oligonucleotides were purchased from MWG-
Biotech AG and the 17-mer was phosphorylated with
phosphatase-dead T4 PNK (Roche) and [g-
32P] ATP.
Preparation of human lymphoblastoid cell-free extracts
Totalcellextractswerepreparedfrom7.5 10
6cellsbylysis
in 300ml 20mM Tris–HCl (pH7.5), 10mM EDTA, 1mM
EGTA, 100mM NaCl, 1% triton-X100 and 1/100 dilution
of protease inhibitor cocktail (Sigma). Extracts were
clariﬁed by centrifugation at 14000rpm for 20min at 4 C,
aliquoted and snap frozen. Protein was quantiﬁed with a
Bio-Rad DC Protein Assay Kit using BSA as a standard.
In vitro DNA phosphatase and DNA kinase reactions
For DNA phosphatase reactions employing recombinant
PNKP, 25nM of the indicated
32P-labelled substrate was
incubated with the indicated concentrations of recombin-
ant protein for 1h at 30 C in 25mM Tris–HCl pH 7.5,
130mM KCl, 10mM MgCl2 and 1mM DTT. Reactions
were stopped by addition of one-third volume of
formamide gel-loading buffer and reaction products
fractionated by 15% denaturing PAGE and analysed by
phosphorimaging. PNKP phosphatase activity was
quantiﬁed by measuring the signal intensity of the 17-P
(substrate) and 17-OH (product) bands using Aida Image
Analyser v.427 and calculating the percentage of substrate
converted to product. For DNA kinase reactions employ-
ing recombinant PNKP, 25nM of the indicated
32P-labelled substrate was incubated with the indicated
concentrations of recombinant protein for 1h at 30 Ci n
25mM Tris–HCl pH 7.5, 130mM KCl, 10mM MgCl2,
50nM ATP, 25nM [g-
32P] ATP (6000Ci/mmol) and
1mM DTT. Reactions were stopped and products
analysed as described above. PNKP kinase activity was
quantiﬁed by phosphorimaging by normalizing the
signal intensity of the labelled 25-mer (product) with the
signal intensity of
32P-labelled 17-mer internal control.
For reactions employing cell-free extract, reactions con-
tained the indicated amounts of extract and 25nM of
the indicated
32P-labelled substrates and were incubated
for the indicated time at 30 C in 25mM Tris–HCl pH 7.5,
130mM KCl, 1mM DTT, 10mM MgCl2. For reactions in
which DNA gap ﬁlling or DNA ligation was measured,
100mM dNTPs or 1mM ATP, respectively, was included
in the reaction buffer. A total of 1000-fold molar excess of
a competitor oligonucleotide of unrelated sequence (50-TC
TGCTAGCATCGATCCATG-30) and harbouring a
50-phosphate and 30-hydroxyl terminus was also included
to reduce degradation of
32P-labelled substrate by non-
speciﬁc nucleases. Reactions were stopped and products
analysed as described above.
For thermal inactivation DNA phosphatase assays, the
indicated concentrations of recombinant PNKP were
pre-incubated for 2min30s at the indicated temperatures
andthenincubatedfor30minwith60nMoftheappropriate
32P-labelledDNAphosphatasesubstrateasdescribedabove.
For thermal inactivation DNA kinase assays, the indicated
concentrations of PNKP were pre-incubated as above at the
indicatedtemperaturesandthenincubatedwith60nMofthe
appropriate
32P-labelledDNAkinasesubstratefor30minat
30 C in 25mM Tris–HCl pH 7.5, 130mM KCl, 10mM
MgCl2,5 0 n MA T P ,2 5 n M[ g-
32P] ATP (6000Ci/mmol)
and 1mM DTT. Reactions were stopped and products
analysed and quantiﬁed as described above.
Cell lines and cell culture
MC22601 and MC22602 are MCSZ lymphoblastoid cells
(LCLs) and are compound heterozygous for the mutations
T424Gfs48X and exon15fs4X. MC22604 and MC22606
are LCLs from unaffected relatives and are heterozygous
carriers of the mutation exon15fs4X. MC5403 is a
MCSZ LCL and is homozygous for the E326K mutation
and MC5405 is a WT LCL from an unaffected relative.
The 1635 is a LCL from an individual with SCAN1 and
AG09387 is a WT LCL from an unrelated individual.
MC22601, MC22606, MC22604, MC22606, MC5403
and MC5405 (12) and 1635 (20) have all been described
previously, and AG09387 was kindly provided by Dr
Mark O’Driscoll.
Flourescence microscopy
A549 cells were seeded onto coverslips (1 10
4/cm
2) and
transfected 48h later with pEYFP constructs encoding
6610 Nucleic Acids Research, 2012,Vol.40, No. 14WT or mutant PNKP using GeneJuice (Novagen) accord-
ing to the manufacturer’s instructions. After 24h, trans-
fected cells were ﬁxed with 4% paraformaldehyde and
permeabilized with 0.5% triton. Nuclear DNA was
counterstained with 40,60-diamidino-2-phenylindole
(DAPI) and YFP positive cells were examined by ﬂuores-
cent microscopy.
Antibodies and immunoblotting
Cells(2 10
5)werelysedinhot(90 C)SDS–PAGEloading
buffer, fractionated by SDS–PAGE, and transferred to
nitrocellulose for immunoblotting with anti-PNK
polyclonal antibody (SK3195) at a concentration of
1/1000 in 1% milk overnight at 4 C.
Alkaline comet assay
LCLs (2 10
5 cells/sample) were mock treated (DMSO
vehicle) or treated with 14mM CPT for the indicated
time periods at 37 C, or alternatively were mock
irradiated or g-irradiated (20Gy) on ice and incubated
at 37 C for the indicated repair periods. Chromosomal
DNA strand breaks were then quantiﬁed using alkaline
comet assays and Comet Assay IV software (Perceptive
Instruments) as previously described (21).
RESULTS
To date, four PNKP mutations have been identiﬁed in
MCSZ (Figure 1) (12). To analyse the impact of these mu-
tations on the DNA 30-phosphatase and DNA 50-kinase
activities of PNKP, recombinant His-PNKP containing
the MCSZ mutations was expressed in E. coli and puriﬁed
by cation exchange chromatography and/or immobilized
metal chelate afﬁnity chromatography (Figure 2A and B;
Supplementary Figure S1). We noted that whereas
PNKP
E326K,P N K P
T424Gfs48X and PNKP
exon15fs4X
exhibited similar chromatographic properties to WT
PNKP during puriﬁcation, PNKP
L176F failed to bind a
cation exchange column (Supplementary Figure S1). As a
negative control for DNA phosphatase activity, we also
expressed and puriﬁed in parallel the protein PNKP
D171N,
which harbours a mutation in the DNA phosphatase
catalytic domain and retains little or no DNA phosphatase
activity (15,22,23).
To measure DNA 30-phosphatase activity we employed a
32P-radiolabelled oligonucleotide duplex that harboured a
1-bp gap with 30-phosphate and 50-phosphate termini
(Figure 2C, top). Strikingly, all of the MCSZ mutant
PNKP proteins exhibited signiﬁcant 30-phosphatase
activity on this substrate, which mimics a common type of
oxidative SSB, as measured by their ability to reduce the
electrophoretic mobility of the
32P-labelled 17-mer
( F i g u r e2 Ca n dD ) .I n d e e dP N K P
E326K,P N K P
T424Gfs48X
andPNKP
exon15fs4XeachpossessedlevelsofDNA30-phos-
phatase activity comparable to WT PNKP (Figure 2C,
right), whereas PNKP
L176F exhibited a modest ( 50%)
reduction in this activity (Figure 2D). In contrast, and in
agreement with previous studies, PNKP
D171N exhibited
greatly reduced DNA 30-phosphatase activity (Figure 2C
and D) (22,23). To measure DNA 50-kinase activity we
employed a
32P-radiolabelled oligonucleotide duplex con-
taining 30-hydroxyl and 50-hydroxyl termini (Figure 3A,
top). Phosphorylation of the 50-terminus of this substrate
by recombinant PNKP, in the presence of [g-
32P] ATP,
was indicated by the appearance of a
32P-labelled 25-mer
product (Figure 3A and B, left). Note that the pre-labelled
32P-17-mer in this substrate served as an internal loading
control. As expected, and in agreement with previous
studies, PNKP
D171N possessed normal levels of DNA
50-kinase activity (Figure 3A and B) (22–24). In contrast,
PNKP
T424Gfs48X and PNKP
exon15fs4X, which contained
large deletions within the DNA kinase domain, possessed
very little DNA 50-kinase activity (Figure 3A). DNA
50-kinase activity was also signiﬁcantly reduced in
PNKP
L176F, despite this mutation being located in the
DNA phosphatase domain (Figure 3B). However,
PNKP
E326K displayed near-normal levels of DNA 50-
kinase activity (Figure 3A).
Next, we examined the impact of MCSZ mutations on
PNKP activity in whole-cell extracts prepared from MCSZ
lymphoblastoid cells (LCLs). For this study, LCLs from
three MCSZ patients and three unaffected relatives were
available for analysis (Figure 1B) [previously described in
(12)]. MC22601 and MC22602 are LCLs from MCSZ
siblingsthatarecompoundheterozygotesforthemutations
T424Gfs48X and exon15fs4X, and MC22604 and
MC22606 are LCLs from unaffected relatives that are
heterozygous for the mutation exon15fs4X. MC5403 is
from an individual with MCSZ that is homozygous for the
E326K mutation, and MC5405 is from a WT unaffected
relative. Cells from MCSZ individuals harbouring
PNKP
L176F are currently not available. In agreement with
our previous report, all of the LCLs from individuals with
MCSZ possessed greatly reduced levels of PNKP protein,
retaining 5–10% of the normal level (Figure 4A) (12).
Consistentwiththis,thethreeMCSZcellextractsexhibited
greatly reduced 30-phosphatase activity on single-stranded
and duplex DNA substrates at 30 C, as measured by the
appearance of dephosphorylated (17-OH) product,
comparedtoextracts fromWT orheterozygousindividuals
(Figure 4B and C). Notably, however, all of the MCSZ
extracts possessed some phosphatase activity, as suggested
by the appearance of an 18-mer product in reactions con-
tainingduplexsubstrate andhighconcentrationsofmutant
cell extract, which reﬂected DNA polymerase activity on
the nascent 30-hydroxyl termini and ﬁlling of the 1-bp gaps
(Figure 4C).
To measure DNA 50-kinase activity in LCL extracts we
employedanoligonucleotideduplexharbouringanickwith
a5 0-hydroxyl terminus present on a 25-mer (Figure 4D,
top). Phosphorylation of the 50-hydroxyl terminus on the
25-merwasmeasuredindirectlyintheseexperiments,bythe
appearance of a 43-bp product resulting from ligation of
the
32P-labelled17-merandthephosphorylated25-mer.We
failed to detect any DNA ligation product in reactions
containing MCSZ cell extract from either MC22601 or
MC22602 LCLs (Figure 4D), consistent with our observa-
tionthatthemutantPNKP
T424Gfs48X andPNKP
exon15fs4X
proteins present in these cell extracts retain very little DNA
kinase activity. In contrast, a small amount DNA ligation
product was observed in reactions containing MCSZ cell
Nucleic Acids Research, 2012,Vol.40, No. 14 6611extract from MC5403 LCLs, suggesting that the greater
residual level of PNKP
E326K in these extracts was sufﬁcient
to support a low level of DNA kinase activity (Figure 4D).
Together, the experiments described above suggest that
the mutant PNKP proteins present in MCSZ cells possess
normal or near-normal levels of DNA phosphatase
activity and also, in the case of PNKP E326K, DNA
kinase activity, as measured in vitro at 30 C, but that
these proteins are unstable in cells. While intracellular in-
stability might be expected for the truncation mutants, it
was more surprising for the point mutant PNKP
E326K.
To address this discrepancy, we examined the thermal
stability of PNKP, PNKP
L176F and PNKP
E326K by
pre-incubating the recombinant proteins at temperatures
that spanned the physiological range (35–38 C) for a short
period (2.5min) prior to measuring their activity at 30 C.
Consistent with the results above, PNKP
E326K protein
that was pre-incubated on ice exhibited near-normal
DNA 30-phosphatase (Figure 5A, left panels) and DNA
50-kinase (Figure 5B, left panels) activity during
Figure 2. DNA 30-phosphatase activity of recombinant PNKP harbouring mutations associated with MCSZ. (A and B) Aliquots of the recombinant
WT and mutant human PNKP (0.7–1mg) employed in these experiments was fractionated by SDS–PAGE and visualized by staining with Coomassie
brilliant blue. Note that the PNKP proteins depicted in panel A were puriﬁed by IMAC/cation exchange and employed in panel C, below, whereas
those depicted in panel B were puriﬁed by IMAC alone and employed in panel D, below. (C and D) DNA 30-phosphatase activities of WT and
mutant PNKP. 25nM of the indicated oligonucleotide duplex substrate (top) was incubated without ( ) or with 2.5, 10, 25 or 50nM of WT or the
indicated mutant PNKP protein for 60min at 30 C. Reaction products were fractionated by denaturing PAGE and detected by phosphorimaging. A
representative gel is shown on the left, and quantiﬁcation from four independent experiments (±SEM) on the right. For quantiﬁcation, the signal
intensities of the 17-P substrate and 17-OH product bands were quantiﬁed using Aida Image Analyser v.427 and the percentage of 17-OH product
calculated. The oligonucleotide duplex contains a 1-bp gap with 30-phosphate and 50-phosphate termini. The position of the 30-phosphate (circled)
and
32P-label on the 17-mer substrate-strand are indicated (top).
6612 Nucleic Acids Research, 2012,Vol.40, No. 14subsequent 30min incubation at 30 C, whereas the
activity of PNKP
L176F was partially reduced. However,
both PNKP
E326K and PNKP
L176F were more sensitive to
pre-incubation at 35 C and 38 C than WT PNKP, with
PNKP
L176F exhibiting the greatest sensitivity (Figure 5A
and B, middle and right panels). These data suggest that
while the L176F and E326K mutations have relatively
small effects on the speciﬁc activity of PNKP
L176F and
PNKP
E326K at 30 C, they confer signiﬁcant instability to
PNKP and reduced activity at physiological temperature.
Finally, we compared the impact of MCSZ mutations
on rates of chromosomal DNA strand break repair in
living cells. To measure chromosomal DNA strand
break repair rates we treated cells with g-radiation,
which induces both SSBs and DSBs of which  70%
harbour 30-phosphate termini, and measured total DNA
strand breakage using alkaline comet assays. The MCSZ
cell lines MC22601 and MC22602, harbouring
PNKP
T424Gfs48X and PNKP
exon15fs4X, exhibited reduced
DNA strand break repair rates following g-radiation, as
did the MCSZ cell line MC5403 harbouring PNKP
E326K
(Figure 6A and B). Since none of the MCSZ mutations
disrupt the nuclear localisation of PNKP [(25) and
Supplementary Figure 2], these experiments suggest that
the reduced total levels of PNKP protein and activity in
MCSZ cells are sufﬁcient to reduce the rate of chromo-
somal DNA strand break repair. We also examined the
impact of MCSZ mutations on the repair of DNA breaks
induced by camptothecin (CPT), a topoisomerase I (Top1)
poison that results in DNA strand breaks (26) possessing
both 30-phosphate and 50-hydroxyl termini (17,20).
Interestingly, while MC22601 and MC22602 MCSZ cells
lines harbouring PNKP
T424Gfs48X and PNKP
exon15fs4X
accumulated elevated levels of DNA strand breaks
during CPT treatment, MC5403 MCSZ cells harbouring
PNKP
E326K did not (Figure 5B and C). This suggests that
Figure 3. DNA 50-kinase activity of recombinant PNKP harbouring mutations associated with MCSZ. (A and B) DNA 50-kinase activity of the
indicated WT and mutant PNKP. 25nM of the indicated substrate (top) was incubated without ( ) or with 10, 25, 50 or 100nM of WT or the
indicated mutant PNKP for 60min at 30 C in the presence of [g-
32P] ATP. Reaction products were fractionated by denaturing PAGE and detected
by phosphorimaging. Note that in the substrate the 17-mer strand is labelled at the 50-terminus with
32P to provide an internal loading control.
A representative gel is shown on the left and quantiﬁcation (mean±SEM) from four independent experiments on the right. For quantiﬁcation, the
signal intensity of the 17-mer and the 25-mer bands were quantiﬁed using Aida Image Analyser v.427 and the intensity of the 25-mer normalized by
dividing by the intensity of the 17-mer.
Nucleic Acids Research, 2012,Vol.40, No. 14 6613Figure 4. PNKP levels and activity in MCSZ lymphoblastoid cell extracts. (A) Western blot analysis of MCSZ LCL. Samples of the indicated LCLs
(2 10
5 cells) were fractionated by SDS–PAGE, transferred to nitrocellulose and immunoblotted for PNKP. Quantiﬁcation is shown on the right.
The signal intensity of PNKP was quantiﬁed using Aida Image Analyser v.427 and normalized using the signal intensity of actin. Data are the mean
± SEM of six experiments. Note that, while not included here, PNKP protein levels in MC22601 were similar to its sibling LCL, MC22602.
(B) Reduced DNA 30-phosphatase activity in MCSZ LCL extract. 25nM single-stranded substrate harbouring a 30-phosphate terminus (top) was
incubated with the indicated LCL extract (2.5mg total protein) for the indicated time periods at 30 C. Reaction products were fractionated by
denaturing PAGE and detected by phosphorimaging. (C) Reduced DNA 30-phosphatase activity in MCSZ LCL extract. 25nM duplex substrate
harbouring a 1-bp gap and 30-phosphate terminus (top) was incubated with the indicated LCL extract (1, 2.5, or 7.5mg total protein) for 60min at
30 C. Reaction products were analysed as above. Note that DNA 30-phosphatase activity is indicated by conversion of 17-P to 17-OH and DNA gap
ﬁlling by conversion of 17-OH to 18-OH. (D) Reduced DNA 50-kinase activity in MCSZ LCL extract. 25nM duplex substrate harbouring a nick and
50-hydroxyl terminus (top) was incubated with the indicated LCL extract (1, 2.5 or 7.5mg total protein) for 60min at 30 C. Reaction products were
analysed as above. Note that DNA 50-kinase activity is indicated indirectly in this experiment by appearance of 43-bp DNA ligation product.
6614 Nucleic Acids Research, 2012,Vol.40, No. 14different MCSZ mutations may impact on DNA strand
break repair rates to a different extent, depending on the
source and/or structure of the DNA break.
DISCUSSION
MCSZ is a human disorder associated with microcephaly,
early-onset seizures and developmental delay (12). MCSZ
results from mutations in PNKP, a DNA end-processing
factor that possesses both DNA 30-phosphatase and DNA
50-kinase activities. To further understand the molecular
defect behind MCSZ, the impact of the four disease-
associated mutations identiﬁed to date on PNKP activity
and rates of chromosomal DNA strand break repair was
examined.
When analysed at 30 C, the truncated MCSZ proteins
PNKP
T424Gfs48X and PNKP
exon15fs4X each exhibited
levels of DNA 30-phosphatase activity comparable to
Figure 5. Thermal stability of WT and mutant recombinant histidine-tagged PNKP. (A) Thermal stability of PNKP DNA phosphatase activity. Top
left, aliquots of the recombinant WT and mutant human PNKP (0.7mg) employed in these experiments was fractionated by SDS–PAGE and
visualized by staining with Coomassie brilliant blue. Note that the PNKP proteins depicted in this panel were puriﬁed by IMAC alone. Middle
and bottom, 30 and 60nM of WT and the indicated mutant PNKP protein were pre-incubated for 2.5min at the indicated temperatures and then
subsequently incubated with 60nM of the indicated oligonucleotide duplex substrate (top) for 30min at 30 C. Reaction products were fractionated
by denaturing PAGE and detected & by phosphorimaging as described in Figure 2. A representative gel is shown in the middle, and the quanti-
ﬁcation from four independent experiments (±SEM) at the bottom. (B) Thermal stability of PNKP DNA kinase activity. Top and bottom, 30, 60
and 120nM of WT and the indicated mutant PNKP protein was pre-incubated for 2.5min at the indicated temperatures and then subsequently
incubated with 60nM of the indicated oligonucleotide duplex substrate (top) for 30min at 30 C in the presence of [g-
32P] ATP. Reaction products
were fractionated by denaturing PAGE and detected and quantiﬁed by phosphorimaging as described in Figure 3. A representative gel is shown at
the top and the quantiﬁcation (mean±SEM) from four independent experiments at the bottom.
Nucleic Acids Research, 2012,Vol.40, No. 14 6615WT. In contrast, these proteins exhibited little DNA 50-
kinase activity, under the same conditions. The absence of
signiﬁcant DNA kinase activity in PNKP
T424Gfs48X and
PNKP
exon15fs4X is not surprising, because of their
extensive deletions within the DNA kinase domain.
However, it is surprising that the speciﬁc activity of the
DNA phosphatase domain is normal, under the condi-
tions examined, because in WT PNKP the phosphatase
Figure 6. Reduced chromosomal SSBR in MCSZ LCLs. (A) The indicated LCLs were mock-irradiated or g-irradiated (20Gy) and incubated for the
indicated time periods at 37 C to allow DNA repair. Levels of chromosomal DNA strand breaks were quantiﬁed by alkaline comet assays as average
tail moments. Data are the mean of 100 cells/time point per experiment and are the average of at least four independent experiments (±SEM). Data
sets for the MCSZ LCLs MC22601, MC22602 and MC5403 were signiﬁcfantly different (two-way ANOVA) to those for the related WT LCLs
MC22606 (P=0.000691), MC22604 (P=0.00158) and MC5405 (P=0.00802), respectively. (B) The indicated LCLs were mock-treated or treated
with 14mM CPT for 60min at 37 C and the level of accumulated chromosomal DNA strand breaks quantiﬁed by alkaline comet assays as average
tail moments, as described above. Data are the mean of 100 cells/time point and are the average of at three independent experiments (±SEM). DNA
sets for the MCSZ LCLs MC22601 and MC22602 were signiﬁcantly different (two-way ANOVA) to those for the related WT LCLs MC22606
(P=0.00172) and MC22604 (P=1.498E-05), respectively. Note that the LCL line 1635 is from an individual with the Tdp1-mutated disease,
SCAN1 and is included as a positive control. (C) The indicated LCLs were mock-treated or treated with 14, 28 or 56mM CPT for 60min at 37 C and
analysed as above. Only the data set for the MCSZ LCL MC22602 was signiﬁcantly different from WT (MC22604; P=3.221E-06).
6616 Nucleic Acids Research, 2012,Vol.40, No. 14and kinase domains form a structural unit that is resistant
to trypsin digestion (15). In the WT enzyme, the structural
unit is stabilized by anchoring of the kinase domain to the
phosphatase domain via interactions between the C-
terminal ﬁve residues (Q517–G521 in human PNKP)
and the interdomain linker/phosphatase domain (15).
Intriguingly, while F518 is lost in PNKP
T424Gfs48X and
PNKP
exon15fs4X, both mutants have acquired a new
phenylalanine at their C-termini as a result of their
frame-shift mutations (F469 in PNKP
T424Gfs48X, which is
471 amino acids in length and F434 in PNKP
exon15fs4X,
which is 436 amino acids in length). Perhaps these novel
phenylalanine residues fulﬁl an analogous role to F518 in
WT PNK, explaining their near-normal DNA phosphat-
ase-speciﬁc activity at 30 C. Despite this, however, levels
of PNKP
T424Gfs48X and PNKP
exon15fs4X protein and
phosphatase activity are greatly reduced in MCSZ cell
extracts, most likely explaining the presence of disease
pathology in affected individuals. Consequently, and
since RT–PCR analysis failed to reveal nonsense
mediated decay of PNKP
T424Gfs48X or PNKP
exon15fs4X
mRNA (12), we suggest that while PNKP
T424Gfs48X and
PNKP
exon15fs4X are stable at 30 C, they are unstable in
cells and present at <10% of normal levels.
In contrast to the truncated mutant proteins, the point
mutantPNKP
E326Kexhibitednear-normalornormallevels
of both DNA 30-phosphatase and DNA 50-kinase activity,
at 30 C. Despite this, the clinical presentation of MCSZ
individuals harbouring the PNKP
E326K mutation is no
less severe than that of the other PNKP mutants (12).
This discrepancy is likely explained by our ﬁnding that,
similar to the truncation mutations, the E326K mutation
results in 10- to 20-fold reduced cellular levels of PNKP
protein. Since reduced PNKP
E326K levels in MCSZ do not
appear to result from mRNA instability (12,27), it is likely
that this point mutant results in signiﬁcant cellular PNKP
instability. Consistent with this idea, while PNKP
E326K
exhibitednear-normalDNAkinase andDNAphosphatase
activity at 30 C, the activity of this mutant protein was
signiﬁcantly reduced at 35–38 C. E326 forms hydrogen
bonds with main chain amides of T323 and A334 and
thereby helps correctly position the seventh a helix in the
DNA phosphatase domain of PNKP (15,28). It is possible
that lysine can be accommodated at this position at 30 C,
but not at physiological temperature.
Of the four MCSZ mutations identiﬁed to date, only
PNKP
L176F exhibited reduced levels of both DNA phos-
phatase and DNA kinase activity, at 30 C. L176 is part of
an important hydrophobic pocket within the DNA
phosphatase domain and is located near to the catalytic
aspartate, D171 (15,28). The benzyl side chain of phenyl-
alanine would most likely not be accommodated within
this pocket and thus cause localized disruption of the
DNA phosphatase domain, which in turn may lead to
mis-folding of the DNA kinase domain. Consistent with
this idea, PNKP
L176F was the only mutant PNKP protein
that displayed altered chromatographic properties during
puriﬁcation. This protein also exhibited signiﬁcant
temperature sensitivity, with both its DNA phosphatase
and DNA kinase activity greatly reduced by incubation
for short periods at physiological temperature. It thus
seems likely that, similar to the other MCSZ PNKP mu-
tations, PNKP
L176F levels will be reduced in MCSZ cells
harbouring this mutation. However, evidence for this
awaits the availability of an appropriate MCSZ cell line.
It is currently unclear whether it is reduced DNA kinase
or DNA phosphatase activity, or both, that accounts for
MCSZ. All MCSZ mutations examined to date result in
>10-fold reductions in PNKP protein level, suggesting
that both DNA 50-kinase and DNA 30-phosphatase
activities are greatly compromised in all MCSZ individ-
uals. In addition, since we detected very little residual
DNA kinase activity in recombinant PNKP
T424Gfs48X or
PNKP
exon15fs4X proteins, even at 30 C, we suggest that
individuals harbouring these mutants are effectively null
for PNKP DNA 50-kinase activity. Consistent with this
idea, we failed to detect any DNA 50-kinase activity in
MCSZ cell extracts harbouring these truncations. In
contrast, all four of the MCSZ mutations identiﬁed to
date confer normal or near-normal levels of DNA phos-
phatase activity in the recombinant proteins at 30 C and,
where examined, detectable levels of DNA 30-phosphatase
activity in protein extracts prepared from MCSZ cells.
Consequently, while it is likely that PNKP DNA 30-phos-
phatase activity is reduced >10-fold in all MCSZ cells, it is
unlikely to be null.
In agreement with their reduced cellular level of PNKP
protein, all MCSZ cells examined to date exhibit reduced
rates of chromosomal DNA strand break repair following
g-irradiation, which induces DNA strand breaks of which
 70% possess 30-phosphate termini. MCSZ individuals
harbouring the PNKP
T424Gfs48X and PNKP
exon15fs4X
mutations also exhibited reduced rates of DNA strand
break repair following treatment with camptothecin
(CPT), a topoisomerase poison that induces SSBs har-
bouring both 30-phosphate and 50-hydroxyl termini.
Interestingly, MCSZ cells harbouring PNKP
E326K
exhibited normal DNA strand break repair rates following
CPT. This may reﬂect the higher residual level of PNKP
protein in MCSZ cell extracts harbouring this mutation,
compared to other PNKP mutations (Figure 5A). It is
worth noting that the reduced rate of DNA strand break
repair observed in MCSZ cells following g-radiation most
likely reﬂects reduced rates of SSB repair, because >95%
of DNA breaks induced by g-rays are SSBs (2,29).
However, it is important to note that PNKP is also
implicated in the repair of DSBs (30–33). Similar to
SSBs, the majority of DNA termini present at DSBs
induced by ROS are 30-phosphate. MCSZ may thus
result from defects in both SSBR and DSBR. Consistent
with this idea, whereas microcephaly is a feature of the
DSBR-defective disorders Lig4 syndrome and human
immunodeﬁciency with microcephaly, seizures have been
reported in patients with SCAN1 and in mice in which
the SSBR protein XRCC1 is conditionally deleted in
brain (11,34–37).
In summary, we report that all of the MCSZ mutations
examined to date result in 10-fold or greater reduced levels
of PNKP protein, due most likely to reduced protein
stability at physiological temperature. While two of the
four mutations effectively ablate cellular PNKP DNA
Nucleic Acids Research, 2012,Vol.40, No. 14 661750-kinase activity, we suggest that none of the mutations
tested to date ablate DNA 30-phosphatase activity.
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